Mercato farmaci anti infettivi arrivera 66 milioni di $

Non si ferma la crescita dei guadagni per il mercato dei farmaci anti infettivi, si prevede che il Mercato dei farmaci anti infettivi arrivera a 66 milioni di $ nel 2013.

[Devi essere iscritto e connesso per vedere questo link]


Anti-Infective Drugs Markets Forecasted to Jump to $66 Billion by 2013
TriMarkPublications.com forecasts in its newly published "Anti-Infective Drugs Markets" report that anti-infective drugs markets will jump to $66 billion by 2013. For more information, visit: [Devi essere iscritto e connesso per vedere questo link]


Anti-infective drugs include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Six infectious diseases -- pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS -- account for half of all premature deaths worldwide. With a worldwide death toll from infectious diseases exceeding 14 million, anti-infective drugs are vital.

To date, the most successful anti-infective drugs target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). Truvada, Valtrex, Cravit, Floxin, Atripla, Pegasys, Kaletra and Reyataz are among the anti-infective drugs with the highest global sales.

The "Anti-Infective Drugs Markets" report covers:
Pneumonia
Influenza
Avian Bird Flu
Sinusitis
Acute Suppurative Thyroiditis
Complicated Skin and Skin Structure Infections (cSSSIs)
Lymphadenitis
Pharyngotonsillitis
Vascular Infections
Pancreatitis
Urinary Tract Infections (UTIs)
Viral Encephalitis
Reye's Syndrome
Blood-Borne Infections
Malaria
West Nile Virus

The "Anti-Infective Drugs Markets" report examines companies manufacturing anti-infective drugs equipment and supplies in the world. Companies covered include: Abraxis Bioscience, Acambis, Achillion, Adlyfe, Advanced Life Sciences Holdings, Affinium, Akonni Biosystems, Alnylam, APP, Aquapharm Biodiscovery, Arbor Vita, Arpida, Avexa, Basilea, Baxter, Biophage Pharma, CEL-SCI, Cerexa, Combimatrix, Cubist, Daiichi Sankyo, Hospira, Idenix, Incyte, Medivir, Meiji Holdings, MerLion, Mutabilis, Nanobio, Nanosphere, Nanoviricides, Novabay, Obetech, Optimer, Panacos, Paratek, Pharmasset, Pico, Polymedix, Powdermed, Presidio, Progenics, Protez, Rib-X, Ribomed, Targanta, Theravance, Trius, Vertex and X-GEN.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit: [Devi essere iscritto e connesso per vedere questo link]

About TriMarkPublications.com

TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit [Devi essere iscritto e connesso per vedere questo link]

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.